
Vall d’Hebron receives funding from ISCIII for LAMA2 research project
We are excited to share that the Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain, has received funding from the…
We are excited to share that the Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain, has received funding from the…
Modalis Therapeutics has made significant strides in developing a gene therapy technology aimed at treating LAMA2-congenital muscular dystrophy (LAMA2-CMD). Earlier…
Dr Reghan Foley has recently started a new research project in collaboration with the University College Cork / Cork’s University…
In september 2023 we started the LAMA2-CMD consortium meetings for researchers, clinicians, companies and patients and their representatives. These meetings…
Professor Dr Madeleine Durbeej of Lund University, Sweden provided an overview of existing research on the mechanisms of LAMA2-CMD and…
Dr Clara Camelo presented key findings from a longitudinal study of Brazilian patients to better understand the correlation between genetic…